Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines

Clinical and Vaccine Immunology

Volumn 19, Issue 10, 2012, Pages 1609-1617

  Plikaytis, Brian D ^a   Stella, Maria ^b   Boccadifuoco, Giuseppe ^b   DeTora, Lisa M ^b   Agnusdei, Mauro ^b   Santini, Laura ^b   Brunelli, Brunella ^b   Orlandi, Luca ^b   Simmini, Isabella ^b   Giuliani, Marzia ^b   Ledroit, Morgan ^c   Hong, Eva ^c   Taha, Muhamed Kheir ^c   Ellie, Kim ^a   Rajam, Gowrisankar ^a   Carlone, George M ^a   Claus, Heike ^d   Vogel, Ulrich ^d   Borrow, Ray ^e   Findlow, Jamie ^e   Gilchrist, Stefanie ^e   Stefanelli, Paola ^f   Fazio, Cecilia ^f   Carannante, Anna ^f   Oksnes, Jan ^g   Fritzsønn, Elisabeth ^g   Klem, Anne Marie ^g   Caugan, Dominique A ^g   Abad, Raquel ^h   Vázquez, Julio A ^h   Rappuoli, Rino ^b   Pizza, Mariagrazia ^b   Donnelly, John J ^b   Medini, Duccio ^b   more..

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM LYSATE; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIAL ADHESIN A; NEISSERIAL HEPARIN BINDING ANTIGEN; UNCLASSIFIED DRUG;

ACCURACY; ANALYSIS OF VARIANCE; ARTICLE; BACTERIAL STRAIN; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; LABORATORY; LIMIT OF QUANTITATION; MENINGOCOCCAL ANTIGEN TYPING SYSTEM; MIXED MODEL ANALYSIS OF VARIANCE; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REPRODUCIBILITY; SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; STANDARDIZATION;

ADHESINS, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PORINS; PROTEIN BINDING;

EID: 84867281306     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00202-12     Document Type: Article

References (27)

1. Bai X, Findlow J, Borrow R. 2001. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin. Biol. Ther. 11:969-985.
2. Bambini S, et al. 2009. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27:2794-2803.
3. Brehony C, Jolley KA, Maiden MC. 2007. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol. Rev. 31: 15-26. (Pubitemid 46058816)
4. Budroni S, et al. 2011. Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc. Natl. Acad. Sci. U. S. A. 108:4494-4499.
5. Caron F, et al. 2011. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect. Dis. 11:455-463.
6. CDC. 2009. Surveillance of invasive bacterial diseases in Europe 2008-2009. Centers for Disease Control and Prevention, Atlanta, GA. http: //www.ecdc.europa.eu/en/publications/Publications/1107-SUR-IBD-2008-09.pdf/.
7. Donnelly J, et al. 2010. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of proteinbased vaccines. Proc. Natl. Acad. Sci. U. S. A. 107:19490-19495.
8. Feil EJ, et al. 2001. Recombination within natural populations of pathogenic bacteria: short-term empirical estimates and long-term phylogenetic consequences. Proc. Natl. Acad. Sci. U. S. A. 98:182-187. (Pubitemid 32095884)
9. Findlow J, et al. 2005. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children. Vaccine 23: 2623-2627. (Pubitemid 40380807)
10. Finne J, Bitter-Suermann D, Goridis C, Finne U. 1987. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J. Immunol. 138:4402-4407. (Pubitemid 17090418)
11. Giuliani MM, et al. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839. (Pubitemid 44148381)
12. Goldblatt D, et al. 2011. Establishment of a new human pneumococcal standard reference serum, 007sp. Clin. Vaccine Immunol. 18:1728-1736.
13. Harrison LH, Trotter CL, Ramsay ME. 2009. Global epidemiology of meningococcal disease. Vaccine 27(Suppl 2):B51-B63.
14. Heyden Y, Smeyers-Verbeke J. 2007. Set-up and evaluation of interlaboratory studies. J. Chromatogr. A 1158:158-167. (Pubitemid 47021138)
15. Holst J, et al. 2009. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis . Vaccine 27(Suppl 2):B3-B12.
16. Jolley KA, Brehony C, Maiden MC. 2007. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol. Rev. 31:89-96. (Pubitemid 46058824)
17. Kapasi A, et al. 2012. Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays. Clin. Vaccine Immunol. 19:64-72.
18. Lin LIK. 1989. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45:255-268.
19. Maiden MC, et al. 1998. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. U. S. A. 95:3140-3145. (Pubitemid 28135868)
20. Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P. 2006. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin. Vaccine Immunol. 13:486-491. (Pubitemid 44044834)
21. Martin SL, et al. 2000. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 18:2476-2481. (Pubitemid 30207032)
22. Rose CE, et al. 2011. Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. Clin. Vaccine Immunol. 18:135-142.
23. Sadarangani M, Pollard AJ. 2010. Serogroup B meningococcal vaccines: an unfinished story. Lancet Infect. Dis. 10:112-124.
24. Snape MD, et al. 2012. The challenge of post-implementation surveillance for novel meningococcal vaccines, Vaccine 30(Suppl 2):B67-B72.
25. Su EL, Snape MD. 2011. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev. Vaccines 10:575-588.
26. Tan LK, Carlone GM, Borrow R. 2010. Advances in the development of vaccines against Neisseria meningitidis . N. Engl. J. Med. 362:1511-1520.
27. Tappero JW, et al. 1999. Immunogenicity of 2 serogroup B outermembrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520-1527. (Pubitemid 29200936)